Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...

She suggested I start taking the GLP-1 Zepbound through weekly injections, along with incorporating a healthy diet and ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

Meanwhile, Novo Nordisk struck deals with several telehealth companies to sell its GLP-1 drug semaglutide for obesity ...

There is a low incidence rate of suicide-related adverse events among adults with diabetes or obesity being treated with GLP-1 RAs.

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

China These authors contributed equally to this work. Correspondence to: Dr. Xi Cao, Beijing Diabetes Institute, Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, No.

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk for falls, and combined use with GLP-1 RAs nearly tripled the risk.

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with T2D.